Vicore Pharma Holding AB VICO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VICO is a good fit for your portfolio.
News
-
Vicore to Present at Upcoming Investor Conferences
-
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
-
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference
-
Vicore Publishes the Annual Report for 2023
-
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
-
Year-end Report 2023
-
Vicore to Present at Upcoming Investor Conferences
-
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
Trading Information
- Previous Close Price
- SEK 17.18
- Day Range
- SEK 16.88–17.54
- 52-Week Range
- SEK 12.36–26.90
- Bid/Ask
- SEK 17.36 / SEK 17.46
- Market Cap
- SEK 1.95 Bil
- Volume/Avg
- 29,311 / 215,368
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 24
- Website
- https://www.vicorepharma.com
Comparables
Valuation
|
Metric
|
VICO
|
CALTX
|
HNSA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.21 | 16.09 | — |
Price/Sales | — | 4.46 | 8.92 |
Price/Cash Flow | — | — | — |
Price/Earnings
VICO
CALTX
HNSA
Financial Strength
|
Metric
|
VICO
|
CALTX
|
HNSA
|
|---|---|---|---|
Quick Ratio | 11.86 | 2.85 | 2.57 |
Current Ratio | 12.10 | 3.13 | 2.66 |
Interest Coverage | −160,931.00 | −5.64 | −7.14 |
Quick Ratio
VICO
CALTX
HNSA
Profitability
|
Metric
|
VICO
|
CALTX
|
HNSA
|
|---|---|---|---|
Return on Assets (Normalized) | −60.43% | −24.68% | −71.82% |
Return on Equity (Normalized) | −67.51% | −89.92% | — |
Return on Invested Capital (Normalized) | −70.37% | −31.14% | −85.22% |
Return on Assets
VICO
CALTX
HNSA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yvncsqnpz | Lbr | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Skffwkzp | Zkpkvq | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xpdcwqfn | Czdjqt | $99.5 Bil | |
MRNA
| Moderna Inc | Mllhjhszt | Pvs | $38.8 Bil | |
ARGX
| argenx SE ADR | Jcgcnrb | Phw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Tyncbtlnw | Cyvz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zbsdyqzg | Rbwzcnh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fttspwq | Wzmxllb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yvhpmcfqr | Cmrswjn | $12.5 Bil | |
INCY
| Incyte Corp | Vffjlslb | Njcrhnw | $11.6 Bil |